Postmenopausal women who progress on fulvestrant ('Faslodex') remain sensitive to further endocrine therapy

Breast Cancer Research and Treatment

Volumn 79, Issue 2, 2003, Pages 207-211

  Vergote, Ignace ^a   Robertson, J F R ^b   Kleeberg, U ^c   Burton, G ^d   Osborne, C K ^e   Mauriac, L ^f  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^c Haematologische/Oncologische Praxis   (Germany)

^d LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^e HOUSTON METHODIST HOSPITAL   (United States)

^f INSTITUT BERGONIÉ   (France)

Author keywords

Advanced breast cancer; Estrogen receptor downregulation; Fulvestrant; Sequential therapy

Indexed keywords

ANASTROZOLE; ANTIESTROGEN; AROMATASE INHIBITOR; FULVESTRANT; LETROZOLE; MEDROXYPROGESTERONE ACETATE; MEGESTROL ACETATE; TAMOXIFEN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BREAST CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG SENSITIVITY; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; ANDROSTENEDIONE; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; ESTRADIOL; ESTROGEN RECEPTOR MODULATORS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MEGESTROL ACETATE; MIDDLE AGED; NITRILES; POSTMENOPAUSE; RETROSPECTIVE STUDIES; SALVAGE THERAPY; TREATMENT OUTCOME; TRIAZOLES;

EID: 0038356602     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1023983032625     Document Type: Article

References (22)

1. Bray F, Sankila R, Ferlay J, Parkin DM: Estimates of cancer incidence and mortality in Europe in 1995. Eur J Cancer 38: 99-166, 2002
2. Nabholtz JM, Buzdar A, Pollak M, Harwin W, Burton G, Mangalik A, Steinberg M, Webster A, von Euler M: Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 18: 3758-3767, 2000
3. Mouridsen H, Gershanovich M, Sun Y, Perez-Carrion R, Boni C, Monnier A, Apffelstaedt J, Smith R, Sleeboom HP, Janicke F, Pluzanska A, Dank M, Becquart D, Bapsy PP, Salminen E, Snyder R, Lassus M, Verbeek JA, Staffler B, Chaudri-Ross HA, Dugan M: Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 19: 2596-2606, 2001
4. Buzdar AU, Hortobagyi G: Update on endocrine therapy for breast cancer. Clin Cancer Res 4: 527-534, 1998
5. Hortobagyi GN: Progress in endocrine therapy for breast carcinoma. Cancer 83: 1-6, 1998
6. Stenbygaard LE, Herrstedt J, Thomsen JF, Svendsen KR, Engelholm SA, Dombernowsky P: Toremifene and tamoxifen in advanced breast cancer - a double-blind cross-over trial. Breast Cancer Res Treat 25: 57-63, 1993
7. Wakeling AE, Dukes M, Bowler J: A potent specific pure anti-estrogen with clinical potential. Cancer Res 51: 3867-3873, 1991
8. Robertson JF, Nicholson RI, Bundred NJ, Anderson E, Rayter Z, Dowsett M, Fox JN, Gee JM, Webster A, Wakeling AE, Morris C, Dixon M: Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5- pentafluoropentylsulfinyl)-nonyl]estra-1,3,5(10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer. Cancer Res 61: 6739-6746, 2001
9. Osborne CK, Jarman M, McCague R, Coronado EB, Hilsenbeck SG, Wakeling AE: The importance of tamoxifen metabolism in tamoxifen-stimulated breast tumor growth. Cancer Chemother Pharmacol 34: 89-95, 1994
10. Osborne CK, Coronado-Heinsohn EB, Hilsenbeck SG, McCue BL, Wakeling AE, McClelland RA, Manning DL, Nicholson RI: Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. J Natl Cancer Inst 87: 746-750, 1995
11. Howell A, DeFriend D, Robertson J, Blamey R, Walton P: Response to a specific antiestrogen (ICI 182780) in tamoxifen-resistant breast cancer. Lancet 345: 29-30, 1995
12. Howell A, DeFriend DJ, Robertson JF, Blamey RW, Anderson L, Anderson E, Sutcliffe FA, Walton P: Pharmacokinetics, pharmacological and anti-tumour effects of the specific anti-oestrogen ICI 182780 in women with advanced breast cancer. Br J Cancer 74: 300-308, 1996
13. Howell A, Robertson JFR, Quaresma Albano J, Aschermannova A, Mauriac L, Kleeberg UR, Vergote I, Erikstein B, Webster A, Morris C: Fulvestrant, formerly ICI 182,780 is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 20: 3396-2403, 2002
14. Osborne CK, Pippen J, Jones SE, Parker LM, Ellis M, Come S, Gertler SZ, May JT, Burton G, Dimery I, Webster A, Morris C, Elledge R, Buzdar A: A double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol 20: 3386-3395, 2002
15. Kaufmann M, Bajetta E, Dirix LY, Fein LE, Jones SE, Cervek J, Fowst C, Polli A, di Salle E, Arkhipov A, Piscitelli G, Massimini G: Survival advantage of exemestane (EXE, Aromasin) over megestrol acetate (MA) in postmenopausal women with advanced breast cancer (ABC) refractory to tamoxifen: results of a phase III randomized double-blind study. Proc Am Soc Clin Oncol 18: 108a, 1999 (abstract 412)
16. Buzdar A, Jonat W, Howell A, Jones SE, Blomqvist C, Vogel CL, Eiermann W, Wolter JM, Azab M, Webster A, Plourde PV: Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group. J Clin Oncol 14: 2000-2011, 1996
17. Dombernowsky P, Smith I, Falkson G, Leonard R, Panasci L, Bellmunt J, Bezwoda W, Gardin G, Gudgeon A, Morgan M, Fornasiero A, Hoffmann W, Michel J, Hatschek T, Tjabbes T, Chaudri HA, Hornberger U, Trunet PF: Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 16: 453-461, 1998
18. Howell A, Howell SJ, Clarke R, Anderson E: Where do selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs) now fit into breast cancer treatment algorithms? J Steroid Biochem Mol Biol 79: 227-237, 2001
19. Robertson JFR, Howell A, Buzdar A, von Euler M, Lee D: Static disease on anastrozole provides similar benefit as objective response in patients with advanced breast cancer. Breast Cancer Res Treat 58: 157-162, 1999
20. Cheung KL, Willsher PC, Pinder SE, Ellis IO, Elston CW, Nicholson RI, Blamey RW, Robertson JF: Predictors of response to second-line endocrine therapy for breast cancer. Breast Cancer Res Treat 45: 219-224, 1997
21. Kurebayashi J, Sonoo H, Inaji H, Nishimura R, Iino Y, Toi M, Kobayashi S, Saeki T: Endocrine therapies for patients with recurrent breast cancer: predictive factors for responses to first- and second-line endocrine therapies. Oncology 59: 31-37, 2000
22. Perey L, Thürlimann B, Hawle H, Bonnefoi H, Aebi A, Pagani O, Goldhirsch A, Dietrich D: Fulvstrant ('Faslodex') as a hormonal treatment in postmenopausal patients with advanced breast cancer progressing after treatment with tamoxifen and non-steroidal aromatase inhibitors: an ongoing phase II SAKK trial. Ann Oncol 13: 172P, 2002